Sunshine Biopharma (SBFM) Depreciation & Amortization - Total (2019 - 2025)
Sunshine Biopharma's (SBFM) quarterly Depreciation & Amortization - Total came in at -$56801.0 in Q4 2025, down 389.79% on a YoY basis from $19600.7 in Q4 2024, and down 159.28% quarter-over-quarter from $95821.0 in Q3 2025.
Powered by 
Analysis
Sunshine Biopharma (SBFM) Depreciation & Amortization - Total (2019 - 2025) Analysis & Trends
Sunshine Biopharma (SBFM) has reported Depreciation & Amortization - Total for 7 consecutive years, with -$56801.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Depreciation & Amortization - Total fell 389.79% year-over-year to -$56801.0; the trailing twelve-month figure through Dec 2025 stood at $176346.0 (up 20.36% YoY), and the FY2025 full-year result was $176346.0, up 20.36% from the prior year.
- Depreciation & Amortization - Total slipped to -$56801.0 in Q4 2025 per SBFM's latest filing, from $95821.0 in the prior quarter.
- Across five years, Depreciation & Amortization - Total topped out at $95821.0 in Q3 2025 and bottomed at -$56801.0 in Q4 2025.
- Historically, Depreciation & Amortization - Total has averaged $22749.3 across 5 years, with a median of $3904.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization - Total soared 4616.1% in 2023, then tumbled 397.05% in 2024.
- Over 5 years, Depreciation & Amortization - Total stood at $3184.0 in 2021, then jumped by 353.99% to $14455.0 in 2022, then slumped by 72.99% to $3904.0 in 2023, then sank by 397.05% to -$11597.0 in 2024, then sank by 389.79% to -$56801.0 in 2025.
- According to Business Quant data, Depreciation & Amortization - Total over the past three periods registered -$56801.0, $95821.0, and $72533.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Tot) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.61 Bn | 38.95 Bn | 2.15 Bn | - |
| 2 | Viatris | 19.18 Bn | 18.30 Bn | 1.46 Bn | - |
| 3 | Dr Reddys Laboratories | 9.85 Bn | 9.68 Bn | 396.53 Mn | - |
| 4 | Amneal Pharmaceuticals | 5.48 Bn | 5.35 Bn | 334.51 Mn | - |
| 5 | Bausch Health Companies | 2.36 Bn | 518.87 Mn | 2.10 Bn | - |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | - |
| 8 | Amphastar Pharmaceuticals | 994.21 Mn | 704.09 Mn | 93.47 Mn | - |
| 9 | Fennec Pharmaceuticals | 405.56 Mn | 364.31 Mn | 17.15 Mn | - |
| 10 | Sunshine Biopharma | 1.56 Mn | -12.19 Mn | 2.43 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -56,801.00 |
| Sep 30, 2025 | 95,821.00 |
| Jun 30, 2025 | 72,533.00 |
| Mar 31, 2025 | 64,793.00 |
| Dec 31, 2024 | -11,597.00 |
| Sep 30, 2024 | 64,627.00 |
| Jun 30, 2024 | 50,870.00 |
| Mar 31, 2024 | 42,618.00 |
| Dec 31, 2023 | 3,904.00 |
| Sep 30, 2023 | 37,210.00 |
| Jun 30, 2023 | 34,877.00 |
| Dec 31, 2022 | 14,455.00 |
| Sep 30, 2022 | 789.00 |
| Jun 30, 2022 | 2,287.00 |
| Mar 31, 2022 | 3,110.00 |
| Dec 31, 2021 | 3,184.00 |
| Sep 30, 2021 | 3,183.00 |
| Jun 30, 2021 | 3,192.00 |
| Mar 31, 2021 | 3,182.00 |
| Dec 31, 2020 | 3,540.00 |